LEO 22811 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2016
At a glance
- Drugs LEO 22811 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- 21 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
- 21 Jan 2010 Actual patient number (58) added as reported by ClinicalTrials.gov.